Navigation Links
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:6/6/2011

SILVER SPRING, Md., June 6, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).  Preliminary analysis demonstrates that the trial has met its primary endpoint.

FREEDOM-M was a randomized, double-blind, placebo-controlled trial of patients with PAH, a chronic, life-threatening illness.  The study enrolled 349 patients who were not receiving any approved PAH medication, with the population for the primary analysis consisting of the 228 patients who had access to the 0.25 mg tablet at randomization.  These patients were administered oral treprostinil or placebo twice daily, with the doses titrated to effect over the course of the 12-week trial.  The majority of patients were in World Health Organization (WHO) Functional Class II (~33%) and Class III (~66%) of varied etiologies, including idiopathic or familial PAH (~75%), collagen vascular disease associated PAH (~19%), and PAH associated with HIV or other associated conditions (~6%).  The patients’ mean baseline six-minute walk distance (6MWD) was approximately 330 meters.

The primary efficacy endpoint of the trial was the change in 6MWD at 12 weeks for the 228 patients.  Preliminary analysis of the FREEDOM-M results demonstrates that those patients receiving oral treprostinil improved their median 6MWD by approximately 23 meters (p=0.0125, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial’s pre-specified statistical analysis plan) as compared to patients receiving placebo.  The median change from baseline was 25 meters for oral treprost
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart failure, ... is scheduled to present at the Bank of America Merrill ... on Thursday, May 14, 2015, at 10:00 a.m. ... the Company,s presentation at the conference will be available via ...
(Date:5/4/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) has ... (Bayer) to develop and commercialize ISIS-FXI Rx for ... agreement, Isis is eligible to receive up to $155 ... up-front payment and a $55 million payment upon advancement ... patients with compromised kidney function. Isis is also eligible ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... Inc. (NASDAQ: MSON ), a medical ... therapeutic ultrasonic products worldwide for wound debridement, cosmetic ... medical applications, today announced plans to release first ... Wednesday, November 9, 2011.  Michael A. McManus, President ...
...  Inova Labs, a privately held medical device company ... Pulmonary Disease (COPD) market, announced today that it has ... up to $17.5M from an investment syndicate led by ... company plans to use the capital to expand its ...
Cached Medicine Technology:Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern 2Inova Labs Closes on $17.5M Series B Financing 2
(Date:5/4/2015)... Fla. (PRWEB) May 04, 2015 ... Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke ... Target: Stroke Honor Roll. The award recognizes the ... patients receive the most appropriate treatment according to ... scientific evidence. , To receive the Gold Plus ...
(Date:5/4/2015)... NORTH HOLLYWOOD, Calif. (PRWEB) May 04, 2015 ... awards program recognizes IPC clinical leaders who have made ... to the patients they serve, both in acute and ... Hospitalist of the Year, Post-Acute Provider of the Year, ... the Year and Specialist Provider of the Year. Recipients ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 ... is now offering a more comfortable and attractive alternative ... restoration of choice for those who have lost teeth. ... can feel insecure or slip at the worst possible ... eats or talks. They can also painfully pinch or ...
(Date:5/4/2015)... May 04, 2015 CCL, a top-ranked, ... this unique program to other leadership development consultancies. “The ... between CCL and successful practitioners, expanding our capacity to ... globe,” said John R. Ryan, CCL President and CEO. ... CCL Partner Network , it will schedule a ...
(Date:5/4/2015)... 2015 Dr. Benjamin Stong of Kalos ... the latest non-surgical double-chin eliminator. Dr. Stong is ... in Atlanta to offer Kybella treatments . The ... specifically under the chin, promising to safely dissolve fat ... patients who sought immediate solutions for their double chin ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2
... Mom,s touch and diet Claire-Dominique Walker, PhD, ... The quality and quantity of maternal milk and maternal-infant ... according to recent research published in Developmental Psychobiology ... early in life can shape the physiology and behaviour ...
... N.C. A multidisciplinary team of University of North Carolina ... grant to develop computer models that will allow physicians to ... airway problems. The three co-principal investigators of the ... Stephanie Davis, MD, Chief of Pediatric Pulmonology in the School ...
... , THURSDAY, Feb. 3 (HealthDay News) -- ... and their doctors better understand the condition, a new ... a personal digital assistant (PDA) device. The patients used ... and other issues three times a day for 30 ...
... ANGELES (Feb. 2, 2011) A team of scientists from ... million grant from the California Institute for Regenerative Medicine ... discoveries for specific diseases. Additionally, another team ... million grant with a medical technology company aiming to develop ...
... HealthDay Reporter , WEDNESDAY, Feb. 2 (HealthDay News) -- ... increasingly common intestinal infection Clostridium difficile , which ... recurrence far better than currently used medications. Researchers ... drug often prescribed to C. difficile patients. ...
... By Maureen Salamon HealthDay Reporter , ... have devised a process to create ready-made, easily stored ... undergoing heart surgery or kidney dialysis. Using donor ... spent more than five years engineering the "off-the-shelf" blood ...
Cached Medicine News:Health News:Brains need love, too 2Health News:UNC researchers developing computer models for pediatric airway problems 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 3Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 2Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 3Health News:Researchers Craft Blood Vessels for Heart, Kidney Patients 2Health News:Researchers Craft Blood Vessels for Heart, Kidney Patients 3
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
... The IMMULITE chemiluminescent immunoassay system ... reliability, high-performance assays and fully integrated ... chosen for various types of immunoassay ... and breadth of menu., Assays for ...
AIA - Nex.IA immunoassay analyzer state of the art automation and flexibility for high throughput immunoassay testing...
... Immunoassay Analyzer that fits in any lab environment. ... 16 X 21 inches and weighs approximately 60 ... office laboratories, work stations for small hospitals, STAT ... a dedicated system for specialty testing. With a ...
Medicine Products: